LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.54 0.94

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.03

Máximo

22.68

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.596 49.052
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+54.5% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-54M 1.6B
Apertura anterior	21.6
Cierre anterior	22.54

Noticias sobre sentimiento de mercado

By Acuity

50%

151 / 344 Clasificación en Healthcare

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jun 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Adquisiciones, fusiones, absorciones

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Charlas de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Ganancias

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Charlas de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Charlas de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Charlas de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Charlas de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Charlas de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Charlas de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Charlas de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Charlas de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Charlas de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Charlas de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Charlas de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Charlas de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

54.5% repunte

Estimación a 12 Meses

Media 34.5 USD 54.5%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

151 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.